Patent Grant
11771852
This disclosure relates to droplet delivery devices and more specifically to droplet delivery devices for the delivery of fluids to the pulmonary system.
The use of aerosol generating devices for the treatment of a variety of respiratory diseases is an area of large interest. Inhalation provides for the delivery of aerosolized drugs to treat asthma, COPD and site-specific conditions, with reduced systemic adverse effects. A major challenge is providing a device that delivers an accurate, consistent, and verifiable dose, with a droplet size that is suitable for successful delivery of medication to the targeted lung passageways.
Dose verification, delivery and inhalation of the correct dose at prescribed times is important. Getting patients to use inhalers correctly is also a major problem. A need exists to insure that patients correctly use inhalers and that they administer the proper dose at prescribed times. Problems emerge when patients misuse or incorrectly administer a dose of their medication. Unexpected consequences occur when the patient stops taking medications, owing to not feeling any benefit, or when not seeing expected benefits or overuse the medication and increase the risk of over dosage. Physicians also face the problem of how to interpret and diagnose the prescribed treatment when the therapeutic result is not obtained.
Currently most inhaler systems such as metered dose inhalers (MDI) and pressurized metered dose inhalers (p-MDI) or pneumatic and ultrasonic-driven devices generally produce droplets with high velocities and a wide range of droplet sizes including large droplet that have high momentum and kinetic energy. Droplets and aerosols with such high momentum do not reach the distal lung or lower pulmonary passageways, but rather are deposited in the mouth and throat. As a result, larger total drug doses are required to achieve the desired deposition in targeted pulmonary areas. These large doses increase the probability of unwanted side effects.
Aerosol plumes generated from current aerosol delivery systems, as a result of their high ejection velocities and the rapid expansion of the drug carrying propellant, may lead to localized cooling and subsequent condensation, deposition and crystallization of drug onto the device surfaces. Blockage of device surfaces by deposited drug residue is also problematic.
This phenomenon of surface condensation is also a challenge for existing vibrating mesh or aperture plate nebulizers that are available on the market. In these systems, in order to prevent a buildup of drug onto mesh aperture surfaces, manufacturers require repeated washing and cleaning, as well as disinfection after a single use in order to prevent possible microbiological contamination. Other challenges include delivery of viscous drugs and suspensions that can clog the apertures or pores and lead to inefficiency or inaccurate drug delivery to patients or render the device inoperable. Also, the use of detergents or other cleaning or sterilizing fluids may damage the ejector mechanism or other parts of the nebulizer and lead to uncertainty as to the ability of the device to deliver a correct dose to the patient or state of performance of the device.
Accordingly, there is a need for a droplet delivery device that delivers droplets of a suitable size range, avoids surface fluid deposition and blockage of apertures, with a dose that is verifiable, and provides feedback regarding correct and consistent usage of the device to patients and professionals such as physicians, pharmacists or therapists.
In one aspect, the disclosure relates to a breath actuated droplet delivery device for delivering a small volume of fluid as an ejected stream of droplets to the pulmonary system of a subject. In certain embodiments, the droplet delivery device is configured to facilitate the ejection of small, e.g., single use, volumes of a therapeutic agent.
In certain embodiments, the droplet delivery device may include: a housing; a mouthpiece positioned at the airflow exit side of the housing; a small volume drug ampoule disposed in or in fluid communication with the housing including a drug reservoir for receiving a small volume of fluid; an ejector mechanism in fluid communication with the reservoir, the ejector mechanism comprising a piezoelectric actuator and an aperture plate, the aperture plate having a plurality of openings formed through its thickness and the piezoelectric actuator operable to oscillate the aperture plate at a frequency to thereby generate an ejected stream of droplets, at least one differential pressure sensor positioned within the housing; the at least one differential pressure sensor configured to activate the ejector mechanism upon sensing a pre-determined pressure change within the mouthpiece to thereby generate an ejected stream of droplets; the ejector mechanism configured to generate the ejected stream of droplets wherein at least about 50% of the droplets have an average ejected droplet diameter of less than about 6 microns, such that at least about 50% of the mass of the ejected stream of droplets is delivered in a respirable range to the pulmonary system of a subject during use. In certain embodiments, the small volume drug ampoule may include a reservoir which comprises an internal flexible membrane separating two internal volumes, a first background pressure fluid volume and a second drug volume.
In some aspects, the droplet delivery device further includes an air inlet flow element positioned in the airflow at the airflow entrance of the device and configured to facilitate non-turbulent (i.e., laminar and/or transitional) airflow across the exit side of aperture plate and to provide sufficient airflow to ensure that the ejected stream of droplets flows through the droplet delivery device during use. In some embodiments, the air inlet flow element may be positioned within the mouthpiece.
In certain embodiments, the housing and ejector mechanism are oriented such that the exit side of the aperture plate is perpendicular to the direction of airflow and the stream of droplets is ejected in parallel to the direction of airflow. In other embodiments, the housing and ejector mechanism are oriented such that the exit side of the aperture plate is parallel to the direction of airflow and the stream of droplets is ejected substantially perpendicularly to the direction of airflow such that the ejected stream of droplets is directed through the housing at an approximate 90 degree change of trajectory prior to expulsion from the housing.
In certain aspects, the droplet delivery device further includes a surface tension plate between the aperture plate and the reservoir, wherein the surface tension plate is configured to increase contact between the volume of fluid and the aperture plate. In other aspects, the ejector mechanism and the surface tension plate are configured in parallel orientation. In yet other aspects, the surface tension plate is located within 2 mm of the aperture plate so as to create sufficient hydrostatic force to provide capillary flow between the surface tension plate and the aperture plate.
In yet other aspects, the aperture plate of the droplet delivery device comprises a domed shape. In other aspects, the aperture plate may be formed of a metal, e.g., stainless steel, nickel, cobalt, titanium, iridium, platinum, or palladium or alloys thereof. Alternatively, the plate can be formed of suitable material, including other metals or polymers, In other aspects. In certain embodiments, the aperture plate is comprised of, e.g., poly ether ether ketone (PEEK), polyimide, polyetherimide, polyvinylidine fluoride (PVDF), ultra-high molecular weight polyethylene (UHMWPE), nickel, nickel-cobalt, palladium, nickel-palladium, platinum, or other suitable metal alloys, and combinations thereof. In other aspects, one or more of the plurality of openings of the aperture plate have different cross-sectional shapes or diameters to thereby provide ejected droplets having different average ejected droplet diameters.
In yet other aspects, the reservoir of the droplet delivery device is removably coupled with the housing. In other aspects, the reservoir of the droplet delivery device is coupled to the ejector mechanism to form a combination reservoir/ejector mechanism module, and the combination reservoir/ejector mechanism module is removably coupled with the housing.
In other aspects, the droplet delivery device may further include a wireless communication module. In some aspects, the wireless communication module is a BLUETOOTH™ transmitter.
In yet other aspects, the droplet delivery device may further include one or more sensors selected from an infer-red transmitter, a photodetector, an additional pressure sensor, and combinations thereof.
In one aspect, the disclosure relates to a method for generating and delivering a fluid as an ejected stream of droplets to the pulmonary system of a subject in a respirable range. The method may comprise: (a) generating an ejected stream of droplets via a breath actuated droplet delivery device of the disclosure, wherein at least about 50% of the ejected stream of droplets have an average ejected droplet diameter of less than about 6 μm; and (b) delivering the ejected stream of droplets to the pulmonary system of the subject such that at least about 50% of the mass of the ejected stream of droplets is delivered in a respirable range to the pulmonary system of a subject during use.
In another aspect, this disclosure relates to a method for delivering a therapeutic agent as an ejected stream of droplets in a respirable range to the pulmonary system of a subject for the treatment of a pulmonary disease, disorder or condition. The method may comprise: (a) generating an ejected stream of droplets via a breath actuated droplet delivery device of the disclosure, wherein at least about 50% of the ejected stream of droplets have an average ejected droplet diameter of less than about 6 μm; and (b) delivering the ejected stream of droplets to the pulmonary system of the subject such that at least about 50% of the mass of the ejected stream of droplets is delivered in a respirable range to the pulmonary system of a subject during use to thereby treat the pulmonary disease, disorder or condition.
In certain embodiments, the pulmonary disease, disorder or condition is selected from asthma, chronic obstructive pulmonary diseases (COPD) cystic fibrosis (CF), tuberculosis, chronic bronchitis, and pneumonia. In other embodiments, the pulmonary disease is lung cancer. In further aspects, the therapeutic agent is a COPD medication, an asthma medication, or an antibiotic. The therapeutic agent may be selected from albuterol sulfate, ipratropium bromide, tobramycin, fluticasone propionate, fluticasone furoate, tiotropium, glycopyrrolate, olodaterol, salmeterol, umeclidinium, and combinations thereof. In yet other aspects, the therapeutic agent may be delivered to the pulmonary system of the subject at a reduced dosage, as compared to standard propellant based inhaler dosages.
In yet another aspect, the disclosure relates to a method for the systemic delivery of a therapeutic agent as an ejected stream of droplets in a respirable range to the pulmonary system of a subject for the treatment of a disease, disorder or condition. The method may comprise: (a) generating an ejected stream of droplets via a piezoelectric actuated droplet delivery device, wherein at least about 50% of the ejected stream of droplets have an average ejected droplet diameter of less than about 6 μm; and (b) delivering the ejected stream of droplets to the pulmonary system of the subject such that at least about 50% of the mass of the ejected stream of droplets is delivered in a respirable range to the pulmonary system of a subject during use to thereby systemically delivery the therapeutic agent to the subject to treat the disease, disorder or condition.
In certain embodiments, the disease, disorder or condition is selected from diabetes mellitus, rheumatoid arthritis, plaque psoriasis, Crohn's disease, hormone replacement therapy, neutropenia, nausea, and influenza.
In further aspects, the therapeutic agent is a therapeutic peptide, protein, antibody, or other bioengineered molecule. In yet further aspects, the therapeutic agent is selected from growth factors, insulin, vaccines, antibodies, Fc-fusion protein, hormones, enzymes, gene therapies and RNAi cell therapies, antibody-drug conjugates, cytokines, anti-infective agents, polynucleotides, oligonucleotides, or any combination thereof. In other aspects, the therapeutic agent is delivered to the pulmonary system of the subject at a reduced dosage, as compared to oral or intravenous dosages.
While multiple embodiments are disclosed, still other embodiments of the present disclosure will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the disclosure. As will be realized, the invention is capable of modifications in various aspects, all without departing from the spirit and scope of the present disclosure. Accordingly, the detailed descriptions are to be regarded as illustrative in nature and not restrictive.
Effective delivery of medication to the deep pulmonary regions of the lungs through the alveoli, has always posed a problem, especially to children and elderly, as well as to those with the diseased state, owing to their limited lung capacity and constriction of the breathing passageways. The impact of constricted lung passageways limits deep inspiration and synchronization of the administered dose with the inspiration/expiration cycle. For optimum deposition in alveolar airways, droplets with aerodynamic diameters in the ranges of 1 to 5 μm are optimal, with droplets below about 4 μm shown to more effectively reach the alveolar region of the lungs, while larger droplets above about 6 μm are deposited on the tongue or strike the throat and coat the bronchial passages. Smaller droplets, for example less than about 1 μm that penetrate more deeply into the lungs have a tendency to be exhaled.
Certain aspects of the disclosure relate to an electronic, fully digital platform for delivery of inhaled therapeutics, described herein as an in-line droplet delivery device or soft mist inhaler (SMI) device with a small volume drug ampoule. In some embodiments, the small volume ampoule is a single use ampoule. The device provides substantial improvements over current inhaled delivery systems by improving dosing precision, dosing reliability, and delivery to the patient. In certain embodiments, the device of the disclosure includes fully integrated monitoring capabilities designed to enhance compliance and ultimately reduce disease associated morbidity.
In certain aspects, the present disclosure relates to an in-line droplet delivery device with a small volume drug ampoule for delivery a fluid as an ejected stream of droplets to the pulmonary system of a subject and related methods of delivering safe, suitable, and repeatable dosages to the pulmonary system of a subject. The present disclosure also includes an in-line droplet delivery device with a small volume drug ampoule and system capable of delivering a defined volume of fluid in the form of an ejected stream of droplets such that an adequate and repeatable high percentage of the droplets are delivered into the desired location within the airways, e.g., the alveolar airways of the subject during use.
The present disclosure provides an in-line droplet delivery device with a small volume drug ampoule for delivery of a fluid as an ejected stream of droplets to the pulmonary system of a subject, the device comprising a housing, a mouthpiece, a small volume drug ampoule including a drug reservoir for receiving a small volume of fluid, and an ejector mechanism including a piezoelectric actuator and an aperture plate, wherein the ejector mechanism is configured to eject a stream of droplets having an average ejected droplet diameter of less than about 6 microns, preferably less than about 5 microns.
In certain embodiments, the small volume drug ampoule may be configured as a single use ampoule (e.g., disposable on a daily or on-use basis). Such embodiments are particularly useful with therapeutic agents that are sensitive to storage conditions, e.g., sensitive to degradation, aggregation, conformational changes, contamination, etc. In this regard, the small volume drug ampoule allows for sterile storage of a therapeutic agent under appropriate conditions until the time of use, e.g., under a temperature controlled environment, as a powder-for-reconstitution, etc. By way of non-limiting example, the small volume drug ampoule of the disclosure is particular suitable for use with therapeutic peptides, proteins, antibodies, and other bioengineered molecules or biologics. However, the disclosure is not so limited, and the small volume drug ampoule may be used with any therapeutic agent known in the art.
Without intending to be limited by theory, in certain aspects, the small volume drug ampoule of the disclosure may offer advantages over larger volume/multi-use ampoules in that, e.g., the limited duration of use minimizes evaporation of fluid in the reservoir, minimizes the possibility of contamination of fluid in the reservoir and/or the ejector surface, minimizes the duration of time of the ampoule is held at non-controlled storage conditions, etc.
In certain embodiments, the small volume drug ampoule includes a drug reservoir for receiving a small volume of fluid, e.g., a volume equivalent to 10 or fewer dosages, a volume equivalent to 5 or fewer dosages, a volume equivalent to 4 or fewer dosages, a volume equivalent to 3 or fewer dosages, a volume equivalent to 2 or fewer dosages, a single dose volume. The small volume drug ampoule is configured to facilitate the ejection of small, e.g., single use, volumes of a therapeutic agent. As will be described in further detail herein, the small volume drug ampoule may include a reservoir which comprises an internal flexible membrane separating two internal volumes, a first background pressure fluid volume and a second drug volume. In certain aspects, the membrane separates the two volumes such that the background pressure fluid volume creates an area of fluid behind/above the drug volume without allowing mixing or diluting of the therapeutic agent by the background pressure fluid. The small volume drug ampoule may further comprise an air exchange vent or air space in the region of the background pressure fluid volume, configured to prevent or relieve the creation of negative pressure during ejection of the drug fluid during use. As described herein, the air exchange vent may include a superhydrophobic filter, optionally in combination with a spiral vapor barrier, which provides for free exchange of air into and out of the reservoir.
As shown in further detail herein, the droplet delivery device is configured in an in-line orientation in that the housing, its internal components, and various device components (e.g., the mouthpiece, air inlet flow element, etc.) are orientated in a substantially in-line or parallel configuration (e.g., along the airflow path) so as to form a small, hand-held device. In certain embodiments, the housing and ejector mechanism are oriented such that the exit side of aperture plate is perpendicular to the direction of airflow and the stream of droplets is ejected in parallel to the direction of airflow. In other embodiments, the housing and ejector mechanism are oriented such that the exit side of aperture plate is parallel to the direction of airflow and the stream of droplets is ejected substantially perpendicularly to the direction of airflow such that the ejected stream of droplets is directed through the housing at an approximate 90 degree change of trajectory prior to expulsion from the housing.
In specific embodiments, the ejector mechanism is electronically breath activated by at least one differential pressure sensor located within the housing of the in-line droplet delivery device upon sensing a pre-determined pressure change within the mouthpiece. In certain embodiments, such a pre-determined pressure change may be sensed during an inspiration cycle by a user of the device, as will be explained in further detail herein.
In some aspects, the droplet delivery device further includes an air inlet flow element positioned in the airflow at the airflow entrance of the housing and configured to facilitate non-turbulent (i.e., laminar and/or transitional) airflow across the exit side of aperture plate and to provide sufficient airflow to ensure that the ejected stream of droplets flows through the droplet delivery device during use. In some embodiments, the air inlet flow element may be positioned within the mouthpiece As will be described in further detail herein, the air inlet flow element may be positioned behind the exit side of the aperture plate along the direction of airflow, or in-line or in front of the exit side of the aperture plate along the direction of airflow. In certain embodiments, the air inlet flow element comprises one or more openings formed there through and configured to increase or decrease internal pressure resistance within the droplet delivery device during use. For instance, the air inlet flow element comprises an array of one or openings. In the embodiments, the air inlet flow element comprises one or more baffles, e.g., wherein the one or more baffles comprise one or more airflow openings.
In accordance with certain aspects of the disclosure, effective deposition into the lungs generally requires droplets less than about 5-6 μm in diameter. Without intending to be limited by theory, to deliver fluid to the lungs a droplet delivery device must impart a momentum that is sufficiently high to permit ejection out of the device, but sufficiently low to prevent deposition on the tongue or in the back of the throat. Droplets below approximately 5-6 μm in diameter are transported almost completely by motion of the airstream and entrained air that carry them and not by their own momentum.
In certain aspects, the present disclosure includes and provides an ejector mechanism configured to eject a stream of droplets within the respirable range of less than about 5-6 μm, preferably less than about 5 μm. The ejector mechanism is comprised of an aperture plate that is directly or indirectly coupled to a piezoelectric actuator. In certain implementations, the aperture plate may be coupled to an actuator plate that is coupled to the piezoelectric actuator. The aperture plate generally includes a plurality of openings formed through its thickness and the piezoelectric actuator directly or indirectly (e.g. via an actuator plate) oscillates the aperture plate, having fluid in contact with one surface of the aperture plate, at a frequency and voltage to generate a directed aerosol stream of droplets through the openings of the aperture plate into the lungs, as the patient inhales. In other implementations where the aperture plate is coupled to the actuator plate, the actuator plate is oscillated by the piezoelectric oscillator at a frequency and voltage to generate a directed aerosol stream or plume of aerosol droplets.
In certain aspects, the present disclosure relates to an in-line droplet delivery device with a small volume drug ampoule for delivering a fluid as an ejected stream of droplets to the pulmonary system of a subject. The ejected stream of droplets includes, without limitation, droplets formed from solutions, suspensions or emulsions which have viscosities in a range capable of droplet formation using the ejector mechanism. In certain aspects, the therapeutic agents may be delivered at a high dose concentration and efficacy, as compared to alternative dosing routes and standard inhalation technologies.
More specifically, the in-line droplet delivery device with a small volume drug ampoule may be used to deliver therapeutic agents as an ejected stream of droplets to the pulmonary system of a subject for the local or systemic delivery of therapeutic agents including small molecules, therapeutic peptides, proteins, antibodies, and other bioengineered molecules via the pulmonary system. In some embodiments, the in-line droplet delivery device may be used to locally or systemically deliver therapeutic agents for the treatment or prevention of cancers, including pulmonary cancers. By way of non-limiting example, the in-line droplet delivery device may be used to systemically deliver therapeutic agents for the treatment or prevention of indications inducing, e.g., diabetes mellitus, rheumatoid arthritis, plaque psoriasis, Crohn's disease, hormone replacement, neutropenia, nausea, influenza, etc.
By way of non-limiting example, therapeutic peptides, proteins, antibodies, and other bioengineered molecules include: growth factors, insulin, vaccines (PREVNORr™—Pneumonia, GARDASIL™—HPV), antibodies (KEYTRUDA™ (pembrolizumab), OPDIVO™ (nivolumab) AVASTIN™ (bevacizumab), HUMIRA™ (adalimumab), REMICADE™ (infliximab), HERCEPTIN™ (trastuzumab)), Fc Fusion Proteins (ENBREL™ (etanercept), ORENCIA™ (abatacept)), hormones (ELONVA™—long acting FSH, Growth Hormone), enzymes (PULMOZYME™—rHu-DNAase—), other proteins (Clotting factors, Interleukins, Albumin), gene therapy and RNAi, cell therapy (PROVENGE™—Prostate cancer vaccine), antibody drug conjugates—ADCETRIS™ (Brentuximab vedotin for HL), cytokines, anti-infective agents, polynucleotides, oligonucleotides (e.g., gene vectors), or any combination thereof, or solid droplets or suspensions such as FLONASE™ (fluticasone propionate) or ADVAIR™ (fluticasone propionate and salmeterol xinafoate).
In other embodiments, the in-line droplet delivery device with a small volume drug ampoule may be used for the treatment or prevention of pulmonary diseases or disorders such as asthma, chronic obstructive pulmonary diseases (COPD) cystic fibrosis (CF), tuberculosis, chronic bronchitis, or pneumonia. In certain embodiments, the in-line droplet delivery device may be used to deliver therapeutic agents such as COPD medications, asthma medications, or antibiotics. By way of non-limiting example, such therapeutic agents include albuterol sulfate, ipratropium bromide, tobramycin, fluticasone propionate, fluticasone furoate, tiotropium, glycopyrrolate, olodaterol, salmeterol, umeclidinium, and combinations thereof.
In other embodiments, the in-line droplet delivery device with a small volume drug ampoule of the disclosure may be used to deliver a solution of nicotine including the water-nicotine azeotrope for the delivery of highly controlled dosages for smoking cessation or a condition requiring medical or veterinary treatment. In addition, the fluid may contain THC, CBD, or other chemicals contained in marijuana for the treatment of seizures and other conditions.
In certain embodiments, the in-line drug delivery device with a small volume drug ampoule of the disclosure may be used to deliver scheduled and controlled substances such as narcotics for the highly controlled dispense of pain medications where dosing is monitored or otherwise controlled. In certain embodiments, by way of non-limiting example, dosing may only enabled by doctor or pharmacy communication to the device, only in a specific location such as the patient's residence as verified by GPS location on the patient's smart phone, and/or it may be controlled by monitoring compliance with dosing schedules, amounts, abuse compliances, etc. In certain aspects, this mechanism of highly controlled dispensing of controlled medications can prevent the abuse or overdose of controlled substances.
Certain benefits of the pulmonary route for delivery of drugs and other medications include a non-invasive, needle-free delivery system that is suitable for delivery of a wide range of substances from small molecules to very large proteins, reduced level of metabolizing enzymes compared to the GI tract and absorbed molecules do not undergo a first pass effect. (A. Tronde, et al., J Pharm Sci, 92 (2003) 1216-1233; A. L. Adjei, et al., Inhalation Delivery of Therapeutic Peptides and Proteins, M. Dekker, New York, 1997). Further, medications that are administered orally or intravenously are diluted through the body, while medications given directly into the lungs may provide concentrations at the target site (the lungs) that are about 100 times higher than the same intravenous dose. This is especially important for treatment of drug resistant bacteria, drug resistant tuberculosis, for example and to address drug resistant bacterial infections that are an increasing problem in the ICU.
Another benefit for giving medication directly into the lungs is that high, toxic levels of medications in the blood stream their associated side effects can be minimized. For example intravenous administration of tobramycin leads to very high serum levels that are toxic to the kidneys and therefore limits its use, while administration by inhalation significantly improves pulmonary function without severe side effects to kidney functions. (Ramsey et al., Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340:23-30; MacLusky et al., Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989; 7:42-48; Geller et al., Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122:219-226.)
As discussed above, effective delivery of droplets deep into the lung airways require droplets that are less than about 5-6 microns in diameter, specifically droplets with mass mean aerodynamic diameters (MMAD) that are less than about 5 microns. The mass mean aerodynamic diameter is defined as the diameter at which 50% of the droplets by mass are larger and 50% are smaller. In certain aspects of the disclosure, in order to deposit in the alveolar airways, droplets in this size range must have momentum that is sufficiently high to permit ejection out of the device, but sufficiently low to overcome deposition onto the tongue (soft palate) or pharynx.
In other aspects of the disclosure, methods for generating an ejected stream of droplets for delivery to the pulmonary system of user using the droplet delivery devices of the disclosure are provided. In certain embodiments, the ejected stream of droplets is generated in a controllable and defined droplet size range. By way of example, the droplet size range includes at least about 50%, at least about 60%, at least about 70%, at least about 85%, at least about 90%, between about 50% and about 90%, between about 60% and about 90%, between about 70% and about 90%, between about 70% and about 95%, etc., of the ejected droplets are in a respirable range of below about 6 μm, preferably below about 5 μm.
In other embodiments, the ejected stream of droplets may have one or more diameters, such that droplets having multiple diameters are generated so as to target multiple regions in the airways (mouth, tongue, throat, upper airways, lower airways, deep lung, etc.) By way of example, droplet diameters may range from about 1 μm to about 200 μm, about 2 μm to about 100 μm, about 2 μm to about 60 μm, about 2 μm to about 40 μm, about 2 μm to about 20 μm, about 1 μm to about 5 μm, about 1 μm to about 4.7 μm, about 1 μm to about 4 μm, about 10 μm to about 40 μm, about 10 μm to about 20 μm, about 5 μm to about 10 μm, and combinations thereof. In particular embodiments, at least a fraction of the droplets have diameters in the respirable range, while other droplets may have diameters in other sizes so as to target non-respirable locations (e.g., larger than about 5 μm). Illustrative ejected droplet streams in this regard might have 50%-70% of droplets in the respirable range (less than about 5 μm), and 30%-50% outside of the respirable range (about 5 μm-about 10 μm, about 5 μm-about 20 μm, etc.)
In another embodiment, methods for delivering safe, suitable, and repeatable dosages of a medicament to the pulmonary system using the droplet delivery devices of the disclosure are provided. The methods deliver an ejected stream of droplets to the desired location within the pulmonary system of the subject, including the deep lungs and alveolar airways.
In certain aspects of the disclosure, an in-line droplet delivery device with a small volume drug ampoule for delivery an ejected stream of droplets to the pulmonary system of a subject is provided. The in-line droplet delivery device with a small volume drug ampoule generally includes a housing, a mouthpiece positioned at the airflow exit side of the housing, a small volume drug ampoule disposed in or in fluid communication with the housing including a drug reservoir for receiving a small volume of fluid, an ejector mechanism in fluid communication with the reservoir, and at least one differential pressure sensor positioned within the housing. In certain embodiments, the small volume drug ampoule may include a reservoir which comprises an internal flexible membrane separating two internal volumes, a first background pressure fluid volume and a second drug volume. The housing, its internal components, and various device components (e.g., the mouthpiece, air inlet flow element, etc.) are orientated in a substantially in-line or parallel configuration (e.g., along the airflow path) so as to form a small, hand-held device. The differential pressure sensor is configured to electronically breath activate the ejector mechanism upon sensing a pre-determined pressure change within the mouthpiece, and the ejector mechanism is configured to generate an ejected stream of droplets.
In certain embodiments, the mouthpiece may be interfaced with (and optionally removable and/or replaceable), integrated into, or part of the housing. In other embodiments, the mouthpiece may be interfaced with (and optionally removable and/or replaceable), integrated into, or part of the drug delivery ampoule.
The ejector mechanism may include a piezoelectric actuator which is directly or indirectly coupled to an aperture plate having a plurality of openings formed through its thickness. The piezoelectric actuator is operable to directly or indirectly oscillate the aperture plate at a frequency to thereby generate an ejected stream of droplets.
In certain embodiments, the housing and ejector mechanism are oriented such that the exit side of aperture plate is perpendicular to the direction of airflow and the stream of droplets is ejected in parallel to the direction of airflow. In other embodiments, the housing and ejector mechanism are oriented such that the exit side of aperture plate is parallel to the direction of airflow and the stream of droplets is ejected substantially perpendicularly to the direction of airflow such that the ejected stream of droplets is directed through the housing at an approximate 90 degree change of trajectory prior to expulsion from the housing.
In certain embodiments, the in-line droplet delivery device with a small volume drug ampoule is comprised of a separate small volume drug delivery ampoule with an ejector mechanism (e.g., combination reservoir/ejector mechanism module) embedded within a surface of a drug reservoir, and a handheld base unit (e.g., housing) including a differential pressure sensor, a microprocessor and three AAA batteries. In certain embodiments, the handheld base unit also includes a mouthpiece, optionally removable, an optional mouthpiece cover, and an optional ejector plate seal. The microprocessor controls dose delivery, dose counting and software designed monitoring parameters that can be transmitted through bluetooth technology. The ejector mechanism optimizes droplet delivery to the lungs by creating an ejected droplet stream in a predefined range with a high degree of accuracy and repeatability. Initial droplet studies show at least 65% to 70% of droplets ejected from the device are in the respirable range (e.g., 1-5 μm).
In certain embodiments, the in-line droplet delivery device with a small volume drug ampoule may include a combination reservoir/ejector mechanism module (e.g., the small volume drug delivery ampoule) that may be replaceable or disposable either on a periodic basis, e.g., a daily, weekly, monthly, as-needed, etc. basis, as may be suitable for a prescription or over-the-counter medication. The reservoir may be prefilled and stored in a pharmacy for dispensing to patients or filled at the pharmacy or elsewhere by using a suitable injection means such as a hollow injection syringe driven manually or driven by a micro-pump. The syringe may fill the reservoir by pumping fluid into or out of a rigid container or other collapsible or non-collapsible reservoir. In certain aspects, such disposable/replaceable, combination reservoir/ejector mechanism module may minimize and prevent buildup of surface deposits or surface microbial contamination on the aperture plate, owing to its short in-use time.
In certain aspects of the disclosure, the ejector mechanism, small volume drug reservoir, and housing/mouthpiece function to generate a plume with droplet diameters less than about 5 um. As discussed above, in certain embodiments, the small volume reservoir and ejector mechanism modules are powered by electronics in the device housing and a reservoir which may carry sufficient drug for a single dose, just a few doses, or several hundred doses of medicament.
The present disclosure also provides an in-line droplet delivery device with a small volume drug ampoule that is altitude insensitive. In certain implementations, the in-line droplet delivery device with a small volume drug ampoule is configured so as to be insensitive to pressure differentials that may occur when the user travels from sea level to sub-sea levels and at high altitudes, e.g., while traveling in an airplane where pressure differentials may be as great as 4 psi. As will be discussed in further detail herein, in certain implementations of the disclosure, the in-line droplet delivery device may include a superhydrophobic filter, optionally in combination with a spiral vapor barrier, which provides for free exchange of air into and out of the reservoir, while blocking moisture or fluids from passing into the reservoir, thereby reducing or preventing fluid leakage or deposition on aperture plate surfaces.
In certain aspects, the devices of the disclosure eliminate the need for patient/device coordination by using a differential pressure sensor to initiate the piezoelectric ejector in response to the onset of inhalation. The device does not require manual triggering of medication delivery. Unlike propellant driven MDIs, the droplets from the devices of the disclosure are generated having little to no intrinsic velocity from the aerosol formation process and are inspired into the lungs solely by the user's incoming breath passing through the mouthpiece. The droplets will ride on entrained air providing improved deposition in the lung.
In certain embodiments, as described in further detail herein, when the drug ampoule is mated to the handheld base unit, electrical contact is made between the base containing the batteries and the ejector mechanism embedded in the drug reservoir. In certain embodiments, visual indications, e.g., a horizontal series of three user visible LED lights, and audio indications via a small speaker within the handheld base unit may provide user notifications. By way of example, the device may be, e.g., 2.0-3.5 cm high, 5-7 cm wide, 10.5-12 cm long and may weight approximately 95 grams with an empty drug ampoule and with batteries inserted.
As described herein, in certain embodiments, the in-line droplet delivery device with a small volume drug ampoule may be turned on and activated for use by inserting the drug ampoule into the base unit, opening the mouthpiece cover, and/or switching an on/off switch/slide bar. In certain embodiments, visual and/or audio indicators may be used to indicate the status of the device in this regard, e.g., on, off, stand-by, preparing, etc. By way of example, one or more LED lights may turn green and/or flash green to indicate the device is ready for use. In other embodiments, visual and/or audio indicators may be used to indicate the status of the drug ampoule, including the number of doses taken, the number of doses remaining, instructions for use, etc. For example, and LED visual screen may indicate a dose counter numerical display with the number of remaining doses in the reservoir.
As described in further detail herein, during use as a user inhales through the mouthpiece of the housing of an in-line droplet delivery device of the disclosure, a differential pressure sensor within the housing detects inspiratory flow, e.g., by measuring the pressure drop across a Venturi plate at the back of the mouthpiece. When a threshold pressure decline (e.g., 8 slm) is attained, the microprocessor activates the ejector mechanism, which in turn generates an ejected stream of droplets into the airflow of the device that the user inhales through the mouthpiece. In certain embodiments, audio and/or visual indicates may be used to indicate that dosing has been initiated, e.g., one or more LEDs may illuminate green. The microprocessor then deactivates the ejector at a designated time after initiation so as to achieve a desired administration dosage, e.g., 1-1.45 seconds. In certain embodiments, as described in further detail herein, the device may provide visual and/or audio indicators to facilitate proper dosing, e.g., the device may emit a positive chime sound after the initiation of dosing, indicating to the user to begin holding their breath for a designated period of time, e.g., 10 seconds. During the breath hold period, e.g., the three green LEDs may blink. Additionally, there may be voice commands instructing the patient on proper times to exhale, inhale and hold their breath, with an audio indicator of a breath hold countdown.
Following dosing, the in-line droplet delivery device with a small volume drug ampoule may turned off and deactivated in any suitable manner, e.g., by closing the mouthpiece cover, switching an on/off switch/slide bar, timing out from non-use, removing the drug ampoule, etc. If desired, audio and/or visual indicators may prompt a user to deactivate the device, e.g., by flashing one or more red LED lights, providing voice commands to close the mouthpiece cover, etc.
In certain embodiments, the in-line droplet delivery device with a small volume drug ampoule may include an ejector mechanism closure system that seals the aperture plate when not in use to protect the integrity of the aperture plate and to minimize and prevent contamination and evaporation of the fluid within the reservoir. For example, in some embodiments, the device may include a mouthpiece cover that comprises a rubber plug that is sized and shaped to seal the exit side surface of the aperture plate when the cover is closed. In other embodiments, the mouthpiece cover may trigger a slide to seal the exit side surface of the aperture plate when the cover is closed. Other embodiments and configurations are also envisioned, e.g., manual slides, covers, and plugs, etc. In certain aspects, the microprocessor may be configured to detect when the ejector mechanism closure, aperture plate seal, etc. is in place, and may thereafter deactivate the device.
Several features of the device allow precise dosing of specific droplet sizes. Droplet size is set by the diameter of the holes in the mesh which are formed with high accuracy. By way of example, the holes in the aperture plate may range in size from 1 μm to 6 μm, from 2 μm to 5 μm, from 3 μm to 5 μm, from 3 μm to 4 μm, etc. Ejection rate, in droplets per second, is generally fixed by the frequency of the aperture plate vibration, e.g., 108-kHz, which is actuated by the microprocessor. In certain embodiments, there is less than a 50-millisecond lag between the detection of the start of inhalation and full droplet generation.
Other aspects of the device of the disclosure that allow for precise dosing of specific droplet sizes include the production of droplets within the respirable range early in the inhalation cycle, thereby minimizing the amount of drug product being deposited in the mouth or upper airways at the end of an inhalation. In addition, the design of the drug ampoule allows the aperture plate surface to be wetted and ready for ejection without user intervention, thus obviating the need for shaking and priming. Further, the design of the drug ampoule vent configuration together with the ejector mechanism closure system limits fluid evaporation from the reservoir to less than 150 μL to 350 μL per month.
The device may be constructed with materials currently used in FDA cleared devices. Standard manufacturing methods may be employed to minimize extractables.
Any suitable material may be used to form the housing of the droplet delivery device. In particular embodiment, the material should be selected such that it does not interact with the components of the device or the fluid to be ejected (e.g., drug or medicament components). For example, polymeric materials suitable for use in pharmaceutical applications may be used including, e.g., gamma radiation compatible polymer materials such as polystyrene, polysulfone, polyurethane, phenolics, polycarbonate, polyimides, aromatic polyesters (PET, PETG), etc.
The small volume drug ampoule may be constructed of any suitable materials for the intended pharmaceutical use. In particular, the drug contacting portions may be made from material compatible with the desired active agent(s). By way of example, in certain embodiments, the drug only contacts the inner side of the drug reservoir and the inner face of the aperture plate and piezoelectric element. Wires connecting the piezoelectric ejector mechanism to the batteries contained in the base unit may be embedded in the drug ampoule shell to avoid contact with the drug. The piezoelectric ejector may be attached to the drug reservoir by a flexible bushing. To the extent the bushing may contact the drug fluid, it may be, e.g., any suitable material known in the art for such purposes such as those used in piezoelectric nebulizers.
Any suitable material known in the art for use in connection with pharmaceutical applications may be used as the ampoule internal membrane, such that the membrane does not interact with the drug fluid or the background pressure fluid, e.g., non-reactive polymer materials. In certain aspects, the membrane is a flexible polymer material, and moves in a direction towards the ejector mechanism surface during use, as the drug fluid is ejected so as to avoid the creation of negative pressure in the drug volume during use. In certain embodiments, the membrane may include pleats or other directional etchings to focus pressure above the area above the ejector mechanism to thereby facilitate an increase in mass loading of the drug fluid to the ejector mechanism, as described below.
Any suitable fluid known in the art for use in connection with pharmaceutical applications may be selected as the background pressure fluid, including but not limited to, saline, distilled water, PBS solution, etc. In certain embodiments, it may be desirable to select a background pressure fluid with similar or the same density as the therapeutic agent fluid so as to substantially match mass loading of the background pressure fluid to that of the therapeutic agent fluid. Without intending to be limited by theory, the background pressure volume of fluid helps to provide a sufficient mass loading of the drug fluid to the ejector mechanism surface. In this regard, insufficient mass loading may result in inefficient wetting of the ejector surface and inefficient ejection of the drug fluid.
In certain embodiments, the device mouthpiece may be removable, replaceable and may be cleaned. Similarly, the device housing and drug ampoule can be cleaned by wiping with a moist cloth. In certain embodiments, the mouthpiece may be interfaced with (and optionally removable and/or replaceable), integrated into, or part of the housing. In other embodiments, the mouthpiece may be interfaced with (and optionally removable and/or replaceable), integrated into, or part of the drug delivery ampoule.
Again, any suitable material may be used to form the mouthpiece of the droplet delivery device. In particular embodiment, the material should be selected such that it does not negatively interact with the components of the device or the fluid to be ejected (e.g., drug or medicament components). For example, polymeric materials suitable for use in pharmaceutical applications may be used including, e.g., gamma radiation compatible polymer materials such as polystyrene, polysulfone, polyurethane, phenolics, polycarbonate, polyimides, aromatic polyesters (PET, PETG), etc. In certain embodiments, the mouthpiece may be removable, replaceable and sterilizable. This feature improves sanitation for drug delivery by providing a mechanism to minimize buildup of aerosolized medication within the mouthpiece and by providing for ease of replacement, disinfection and washing. In one embodiment, the mouthpiece tube may be formed from sterilizable and transparent polymer compositions such as polycarbonate, polyethylene or polypropylene, as discussed herein.
In certain aspects of the disclosure, an electrostatic coating may be applied to the one or more portions of the housing, e.g., inner surfaces of the housing along the airflow pathway such as the mouthpiece, to aid in reducing deposition of ejected droplets during use due to electrostatic charge build-up. Alternatively, one or more portions of the housing may be formed from a charge-dissipative polymer. For instance, conductive fillers are commercially available and may be compounded into the more common polymers used in medical applications, for example, PEEK, polycarbonate, polyolefins (polypropylene or polyethylene), or styrenes such as polystyrene or acrylic-butadiene-styrene (ABS) copolymers. Alternatively, in certain embodiments, one or more portions of the housing, e.g., inner surfaces of the housing along the airflow pathway such as the mouthpiece, may be coated with anti-microbial coatings, or may be coated with hydrophobic coatings to aid in reducing deposition of ejected droplets during use. Any suitable coatings known for such purposes may be used, e.g., polytetrafluoroethylene (Teflon).
Any suitable differential pressure sensor with adequate sensitivity to measure pressure changes obtained during standard inhalation cycles may be used, e.g., ±5 SLM, 10 SLM, 20 SLM, etc. For instance, pressure sensors from Sensirion, Inc., SDP31 or SDP32 (U.S. Pat. No. 7,490,511 B2) are particularly well suited for these applications.
In certain aspects, the microprocessor in the device may be programmed to ensure exact timing and actuation of the ejector mechanism in accordance with desired parameters, e.g., based duration of piezoelectric activation to achieve desired dosages, etc. In certain embodiments, the device includes or interfaces with a memory (on the device, smartphone, App, computer, etc.) to record the date-time of each ejection event, as well as the user's inhalation flow rate during the dose inhalation to facilitate user monitoring, as well as drug ampoule usage monitoring. For instance, the microprocessor and memory can monitor doses administered and doses remaining in a particular drug ampoule. In certain embodiments, the drug ampoule may comprise components that include identifiable information, and the base unit may comprise components that may “read” the identifiable information to sense when a drug ampoule has been inserted into the base unit, e.g., based on a unique electrical resistance of each individual ampoule, an RFID chip, or other readable microchip (e.g., cryptoauthentication microchip). Dose counting and lockouts may also be preprogramed into the microprocessor.
In certain embodiments of the present disclosure, the signal generated by the pressure sensors provides a trigger for activation and actuation of the ejector mechanism to thereby generate droplets and delivery droplets at or during a peak period of a patient's inhalation (inspiratory) cycle and assures optimum deposition of the plume of droplets and delivery of the medication into the pulmonary airways of the user.
In accordance with certain aspects of the disclosure, the in-line droplet delivery device with a small volume drug ampoule provides a reliable monitoring system that can date and time stamp actual delivery of medication, e.g., to benefit patients through self-monitoring or through involvement of care givers and family members.
As described in further detail herein, the in-line droplet delivery device with a small volume drug ampoule of the disclosure may detect inspiratory airflow and record/store inspiratory airflow in a memory (on the device, smartphone, App, computer, etc.). A preset threshold (e.g., 8-10 slm) triggers delivery of medication over a defined period of time, e.g., 1-1.5 seconds. Inspiratory flow is sampled frequently until flow stops. The number of times that delivery is triggered is incorporated and displayed in the dose counter LED on the device. Blue tooth capabilities permit the wireless transmission of the data.
BLUETOOTH™ communication in the device will communicate date, time and number of actuations per session to the user's smartphone. Software programing can provide charts, graphics, medication reminders and warnings to patients and whoever is granted permission to the data. The software application will be able to incorporate multiple medications that use the device of the disclosure (e.g. albuterol, inhaled steroid, etc.). The device of the disclosure can also provide directed instruction to users, including audio and visual indicators to facilitate proper use of the device and proper dosing.
The device of the present disclosure is configured to dispense droplets during the correct part of the inhalation cycle, and can including instruction and/or coaching features to assist patients with proper device use, e.g., by instructing the holding of breath for the correct amount of time after inhalation. The device of the disclosure allows this dual functionality because it may both monitor air flow during the inhalation, and has internal sensors/controls which may detect the end of inhalation (based upon measured flow rate) and can cue the patient to hold their breath for a fixed duration after the inhalation ceases.
In one exemplary embodiment, a patient may be coached to hold their breath with an LED that is turned on at the end of inhalation and turned off after a defined period of time (i.e., desired time period of breath hold), e.g., 10 seconds. Alternatively, the LED may blink after inhalation, and continue blinking until the breath holding period has ended. In this case, the processing in the device detects the end of inhalation, turns on the LED (or causes blinking of the LED, etc.), waits the defined period of time, and then turns off the LED. Similarly, the device can emit audio indications, e.g., one or more bursts of sound (e.g., a 50 millisecond pulse of 1000 Hz), verbal instructions to hold breath, verbal countdown, music, tune, melody, etc., at the end of inhalation to cue a patient to hold their breath for the during of the sound signals. If desired, the device may also vibrate during or upon conclusion of the breath holding period.
In certain embodiments, the device provides a combination of audio and visual methods (or sound, light and vibration) described above to communicate to the user when the breath holding period has begun and when it has ended. Or during the breath holding to show progress (e.g., a visual or audio countdown).
In other aspects, the device of the disclosure may provide coaching to inhale longer, more deeply, etc. The average peak inspiratory flow during inhalation (or dosing) can be utilized to provide coaching. For example, a patient may hear a breath deeper command until they reach 90% of their average peak inspiratory flow as measured during inspiration (dosing) as stored on the device, phone or in the cloud.
In addition, an image capture device, including cameras, scanners, or other sensors without limitation, e.g. charge coupled device (CCD), may be provided to detect and measure the ejected aerosol plume. These detectors, LED, delta P transducer, CCD device, all provide controlling signals to a microprocessor or controller in the device used for monitoring, sensing, measuring and controlling the ejection of a plume of droplets and reporting patient compliance, treatment times, dosage, and patient usage history, etc., via BLUETOOTH™, for example.
Reference will now be made to the figures, with like components illustrates with like references numbers.
In the embodiment shown in
With reference to
The components may be packaged in a housing, and generally oriented in an in-line configuration. The housing may be disposable or reusable, single-dose or multi-dose. Although various configurations to form the housing are within the scope of the disclosure, as illustrated in
In certain embodiments, the device may include audio and/or visual indications, e.g., to provide instructions and communications to a user. In such embodiments, the device may include a speaker or audio chip (not shown), one or more LED lights 216, and LCD display 217 (interfaced with an LCD control board 218 and lens cover 219). The housing may be handheld and may be adapted for communication with other devices via a BLUETOOTH™ communication module or similar wireless communication module, e.g., for communication with a subject's smart phone, tablet or smart device (not shown).
In certain embodiments, an air inlet flow element (not shown, see, e.g.,
By way of non-limiting example, an exemplary method of insertion of an ampoule through to use and powering off of the device may be performed as follows:
More particularly, a specific exemplary embodiment of a mode of operation of insertion of a drug ampoule and operation of a device is illustrated in
Referring to
Referring to
However, it is noted that the devices and methods of the disclosure are not so limited, and various modifications and expansions of the method of operation is envisioned as within the scope of the disclosure.
For instance, the small volume drug ampoule may be used in a simple “snap-on” or “clip-in” configuration, which automatically activates the device. In particular, in the context of the small volume drug ampoule, as longer term use and storage of the fluid reservoir on the device is not required, in certain embodiments, the small volume ampoule configuration may not require an aperture plate seal or cover in all embodiments, e.g., to maintain sterility and/or minimize evaporation of the therapeutic agent fluid. Further, in certain embodiments, the device may be configured, e.g., through on-board software, to prompt a user to take multiple breaths to ensure that the entire volume of therapeutic agent is ejected (e.g., through counting breath activations, monitoring volume of ejected droplets, etc.). In such embodiments, the device may be configured to ensure dosing accuracy is maintained.
In another embodiment,
In the embodiment shown in
With reference to
In certain embodiments, the reservoir may be a single use reservoir that may be replaceable, disposable or reusable. As illustrated in
The components may be packaged in a housing, and generally oriented in an in-line configuration. The housing may be disposable or reusable, single-dose or multi-dose. Although various configurations to form the housing are within the scope of the disclosure, as illustrated in
In certain embodiments, the device may include audio and/or visual indications, e.g., to provide instructions and communications to a user. In such embodiments, the device may include a speaker or audio chip 520, one or more LED lights 516, and LCD display 517 (interfaced with an LCD control board 518 and lens cover 519). The housing may be handheld and may be adapted for communication with other devices via a BLUETOOTH™ communication module or similar wireless communication module, e.g., for communication with a subject's smart phone, tablet or smart device (not shown).
With reference to
As discussed herein, the drug reservoir and/or small volume drug ampoule may include various vents and/or vapor barriers to facilitate venting, etc. With reference to
In accordance with aspects, the in-line droplet delivery devices with small volume drug ampoules of the disclosure may include an air inlet flow element (see, e.g.,
In accordance with certain embodiments of the in-line droplet delivery device with small volume drug ampoules of the disclosure, the device may include an air inlet flow element may be positioned in the airflow at the airflow entrance of the device and configured to facilitate non-turbulent (i.e., laminar and/or transitional) airflow across the exit side of aperture plate and to provide sufficient airflow to ensure that the ejected stream of droplets flows through the droplet delivery device during use. In some embodiments, the air inlet flow element may be positioned within the mouthpiece. In addition, the air inlet flow element allows for customization of internal device pressure resistance by designing openings of different sizes and varying configurations to selectively increase or decrease internal pressure resistance.
As will be described in further detail herein, the air inlet flow element may be positioned behind the exit side of the aperture plate along the direction of airflow, or in-line or in front of the exit side of the aperture plate along the direction of airflow. In certain embodiments, the air inlet flow element comprises one or more openings formed there through and configured to increase or decrease internal pressure resistance within the droplet delivery device during use. For instance, the air inlet flow element comprises an array of one or openings. In the embodiments, the air inlet flow element comprises one or more baffles, e.g., wherein the one or more baffles comprise one or more airflow openings.
In certain embodiments, the air inlet flow element is designed and configured in order to provide an optimum airway resistance for achieving peak inspirational flows that are required for deep inhalation which promotes delivery of ejected droplets deep into the pulmonary airways. Air inlet flow elements also function to promote non-turbulent flow across the aerosol plume exit port, which also serves to stabilize airflow repeatability, stability and insures an optimal precision in the delivered dose.
Without intending to be limited by theory, in accordance with aspects of the disclosure, the size, number, shape and orientation of flow restrictions (e.g., openings, holes, flow blocks, etc.) in the air inlet flow element of the disclosure may be configured to provide a desired pressure drop within the in-line droplet delivery device. In certain embodiments, it may be generally desirable to provide a pressure drop that is not so large as to strongly affect a user's breathing or perception of breathing.
In certain implementations, the use of air inlet flow elements having differently configured, sized, and shaped flow restrictions (e.g., openings, holes, flow blocks, etc.), or the use of adjustable apertures may be required in order to accommodate the differences among the lungs and associated inspiratory flow rates of young and old, small and large, and various pulmonary disease states. For example, if the aperture is adjustable by the patient (perhaps by having a slotted ring that can be rotated), then a method may be provided to read the aperture hole setting and lock that position to avoid inadvertent changes of the aperture hole size, hence the flow measurement. Although pressure sensing is an accurate method for flow measurement, other embodiments may use, e.g., hot wires or thermistor types of flow rate measurement methods which lose heat at a rate proportional to flow rate, moving blades (turbine flow meter technology) or by using a spring-loaded plate, without limitation of example.
For instance,
More particularly,
In this regard,
Inspiratory Flow Rate (SLM)=C(SqRt)(Pressure(Pa))
A particular non-limiting exemplary air inlet flow element may 29 holes, each 1.9 mm in diameter. However, the disclosure is not so limited. For example, the air inlet flow element may have hole diameters ranging from, e.g., 0.1 mm in diameter to diameters equal to the cross sectional diameter of the air inlet tube (e.g., 0.5 mm, 1 mm, 1.5 mm, 2 mm, 2.5 mm, 3 mm, 3.5 mm, 4 mm, 4.5 mm, 5 mm, 5.5 mm, 6 mm, 6.5 mm, etc.), and number of holes may range from 1 to the number of holes, for example, to achieve the desire air flow resistance, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 29, 30, 60, 90, 100, 150, etc.
In accordance with the disclosure, it has been found that the presence of inner air inlet flow elements generally improve spray efficiency for exemplary fluid solutions (deionized water and albuterol solution. For instance, as shown in
In certain aspects of the disclosure, the in-line device with small volume drug ampoule may optionally be configured to protect the surface of the aperture plate, to minimize evaporation losses, and to minimize contamination while the device is closed and not in use. However, as mentioned above, in the context of the small volume drug ampoule, as longer term use and storage of the fluid reservoir on the device is not required, in certain embodiments, the small volume ampoule configuration may not require an aperture plate seal or cover in all embodiments, e.g., to maintain sterility and/or minimize evaporation of the therapeutic agent fluid.
For instance, as described herein, when the reservoir/ampoule is in the closed position, the surface of the aperture plate of the ejector mechanism may be closed/sealed against the housing or the mouthpiece cover. However, in certain embodiments, when the reservoir/ampoule includes an O-ring or gasket to facilitate the seal of the surface of the aperture plate of the ejector mechanism, the sliding of the reservoir/ampoule between the open and closed position may, in certain aspects, create friction which needs to be overcome by a compression spring during opening and closing.
In one embodiment, friction between the ampoule O-ring and the device housing may be reduced by applying a compressive force between the ampoule and the device housing in the last few millimeters as the ampoule is closed. Thus, higher friction is limited to the first few millimeters during opening, when the compression spring is providing the highest force; and during the last few millimeters of closing when the ampoule door is almost closed and force on the door is easiest for the user to apply. Force applied as the door is almost closed also creates minimal reaction forces at the door's hinge, improving robustness of the device. Applying pressure to the O-ring over a shorter distance also reduces wear on the O-ring (or gasket).
Without being limited, in certain embodiments, applying a compressive sealing force during the last few millimeters of ampoule motion to the closed position can be accomplished by utilizing a ramp on either the ampoule or device side of the ampoule track which engages a budge on the opposite face (device for ampoule or ampoule for device) as the ampoule approaches the closed position. This can also be a pair of ramps which engage as the ampoule approaches the closed position. In certain aspects, the point(s) of contact between the ampoule and device should be in alignment with the center of pressure of the O-ring to create a uniform sealing pressure. Note that to achieve enough compression for good sealing, the total vertical motion created by the ramp only needs to be in the range of 0.1 mm.
Alternatively to a sealing force generated by a fixed movement of the ampoule towards the device, a flexible compressive element can apply a downward force the rises as the ampoule approaches the closed position. By way of non-limiting example, this could be the ramp intersecting a flexible, rubber-like, material or a metallic or plastic spring, including a cantilever (leaf) spring that the ramp encounters as it arrives at the closed position of the ampoule.
The compressive force applied to the O-ring does not have to be large, but sufficient for the compliant O-ring to seal against the surface roughness of the device surface. In certain embodiments, a more compliant material will require less compressive force to seal. Similarly, the O-ring can be made from a slippery material such as teflon-coated or teflon-encapsulated material to reduce the sliding friction of the ampoule. Similarly, sealing may be done by a lip seal at the face.
In other embodiments, the surface of the aperture plate may be protected by the mouthpiece cover. For instance, as shown in
In certain embodiments, as illustrated herein, the reservoir/cartridge module may include components that may carry information read by the housing electronics including key parameters such as ejector mechanism functionality, drug identification, and information pertaining to patient dosing intervals. Some information may be added to the module at the factory, and some may be added at the pharmacy. In certain embodiments, information placed by the factory may be protected from modification by the pharmacy. The module information may be carried as a printed barcode or physical barcode encoded into the module geometry (such as light transmitting holes on a flange which are read by sensors on the housing). Information may also be carried by a programmable or non-programmable microchip on the module which communicates to the electronics in the housing.
By way of example, module programming at the factory or pharmacy may include a drug code which may be read by the device, communicated via BLUETOOTH™ to an associated user smartphone and then verified as correct for the user. In the event a user inserts an incorrect, generic, damaged, etc., module into the device, the smartphone might be prompted to lock out operation of the device, thus providing a measure of user safety and security not possible with passive inhaler devices. In other embodiments, the device electronics can restrict use to a limited time period (perhaps a day, or weeks or months) to avoid issues related to drug aging or build-up of contamination or particulates within the device housing.
The in-line droplet delivery device may further include various sensors and detectors to facilitate device activation, spray verification, patient compliance, diagnostic mechanisms, or as part of a larger network for data storage, big data analytics and for interacting and interconnected devices used for subject care and treatment, as described further herein. Further, the housing may include an LED assembly on a surface thereof to indicate various status notifications, e.g., ON/READY, ERROR, etc.
The airflow exit of the housing of the droplet delivery device through which the ejected plume of droplets exit as they are inhaled into a subject's airways, may be configured and have, without limitation, a cross sectional shape of a circle, oval, rectangular, hexagonal or other shape, while the shape of the length of the tube, again without limitation, may be straight, curved or have a Venturi-type shape.
In another embodiment (not shown), a mini fan or centrifugal blower may be located at the air inlet side of the laminar flow element or internally of the housing within the airstream. The mini fan generally may provide additional airflow and pressure to the output of the plume. For patients with low pulmonary output, this additional airplume may ensure that the plume of droplets is pushed through the device into the patient's airway. In certain implementations, this additional source of airflow ensures that the plume exit port is swept clean of the droplets and also provides mechanism for spreading the particle plume into an airflow which creates greater separation between droplets. The airflow provided by the mini fan may also act as a carrier gas, ensuring adequate dose dilution and delivery.
In other embodiments, the internal pressure resistance of the in-line droplet delivery device may be customized to an individual user or user group by modifying the mouthpiece tube design to include various configurations of air aperture grids or openings, thereby increasing or decreasing resistance to airflow through the device as the user inhales. For instance, different air entrance aperture sizes and numbers may be used to achieve different resistance values, and thereby different internal device pressure values. This feature provides a mechanism to easily and quickly adapt and customize the airway resistance of the particle delivery device to the individual patient's state of health or condition.
In another aspect of the disclosure, in certain embodiments, the in-line droplet delivery devices provide for various automation, monitoring and diagnostic functions. By way of example, as described above, device actuation may be provided by way of automatic subject breath actuation. Further, in certain embodiments, the device may provide automatic spray verification, to ensure that the device has generated the proper particle generation and provided to proper dosing to the subject. In this regard, the particle delivery device may be provided with one or more sensors to facilitate such functionality.
For instance, an airflow sensor located in the mouthpiece may measure inspiratory and expiratory flow rates. This sensor is placed so that it does not interfere with drug delivery or become a site for collection of residue or promote bacterial growth or contamination. A differential (or gage) pressure sensor downplume of a flow restrictor (e.g., air inlet flow element) measures airflow based upon the pressure differential between the inside of the mouthpiece relative to the outside air pressure. During inhalation (inspiratory flow) the mouthpiece pressure will be lower than the ambient pressure and during exhalation (expiratory flow) the mouthpiece pressure will be greater than the ambient pressure. The magnitude of the pressure differential during an inspiratory cycle is a measure of the magnitude of airflow and airway resistance at the air inlet end of the delivery tube.
Again, a BLUETOOTH™ communication module or similar wireless communication module may be provided in order to link the droplet delivery device to a smartphone or other similar smart devices (not shown). BLUETOOTH™ connectivity facilitates implementation of various software or App's which may provide and facilitate patient training on the use of the device. A major obstacle to effective inhaler drug therapy has been either poor patient adherence to prescribed aerosol therapy or errors in the use of an inhaler device. By providing a real time display on the smartphone screen of a plot of the patient's inspiratory cycle, (flow rate versus time) and total volume, the patient may be challenged to reach a goal of total inspiratory volume that was previously established and recorded on the smartphone during a training session in a doctor's office. BLUETOOTH™ connectivity further facilitates patient adherence to prescribed drug therapy and promotes compliance by providing a means of storing and archiving compliance information, or diagnostic data (either on the smartphone or cloud or other large network of data storage) that may be used for patient care and treatment.
More specifically, in certain embodiments, the droplet delivery device may provide automatic spray verification via LED and photodetector mechanisms. For instance, an infra-red transmitter (e.g., IR LED, or UV LED<280 nm LED), and infra-red or UV (UV with <280 nm cutoff) photodetector may be mounted along the droplet ejection side of the device to transmit an infra-red or UV beam or pulse, which detects the plume of droplets and thereby may be used for spray detection and verification. The IR or UV signal interacts with the aerosol plume and can be used to verify that a plume of droplets has been ejected as well as provide a measure of the corresponding ejected dose of medicament. Examples include but not limited to, infrared 850 nm emitters with narrow viewing angles of either, 8, 10 and 12-degrees, (MTE2087 series) or 275 nm UV LED with a GaN photodetector for aerosol plume verification in the solar blind region of the spectra. Alternatively in some applications, the sub 280 nm LEDs (e.g. 260 nm LEDs) can be used to disinfect the spacer tube.
By way of example, the concentration of a medicament in the ejected fluid may be made, according to Beer's Law Equation (Absorbance=e L c), where, e is the molar absorptivity coefficient (or molar extinction coefficient) which is a constant that is associated with a specific compound or formulation, L is the path length or distance between LED emitter and photodetector, and c is the concentration of the solution. This implementation provides a measure of drug concentration and can be used for verification and a means and way to monitoring patient compliance as well as to detect the successful delivery of medication.
In another embodiment, spray verification and dose verification can be monitored by measuring the transmission of 850 nM to 950 nM light across the spray in a region where the droplets are not variably diluted with different inhalation flow rates. The average and alternating signals from the detector may be measured to calibrate and confirm the optical path (average signal) and detect the spray (alternating signal). In practice, the alternating signal can be measured by a 100 Hz low-pass filter between the detector and analog converter, sampling the signal 100 to 500 times a second, calculating the average and the range (maximum minus minimum) over 100 mS periods, and comparing these values to preset values to confirm proper operation and whether there was spray or not.
This method has the strong advantages of: low power consumption (less than 1 ma to the emitter); unaffected by stray light (visible light blocking on the detector); relatively resistant to digital noise or the 100 kHz piezo drive by the 100 Hz low-pass filter; the average signal level can be used to adjust the optical path for attenuation caused by drug deposits on the LED or detector; and simple hardware with a positive signal that is robustly measured.
This system also allows simple regulation of the optical signal strength by increasing power to the emitter should the average signal level decrease. Practically, this means using pulse width modulation of emitter current to regulate average emitter power. The pulses should be at a high rate, e.g., 100 kHz, so that this noise can be removed by the 100 Hz low pass filter. Nominal operation might use a 10% duty cycle of 10 mA to achieve and average current of 1 mA. This system would have the ability to increase the average current to 10 mA and correct for up to a factor of 10 attenuation by drug deposits.
In operation with the 950 nM emitter and detector having angles of +−20 degrees and spaced 10 mm apart. With 0.5 mA emitter power, a 10K collector resistor and 100 Hz low-pass filter, the average signal output is 2 volts and the peak to peak value of the alternating component is 4 mV without spray and 40 mV during spray. Without intending to be limited, in practice, there may be a transient large peak to peak value when the spray begins and ends as the bulk attenuation causes a large shift. The resistor sizing here is for continuous running of the emitter and not PWM.
All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically, and individually, indicated to be incorporated by reference.
While the invention has been described with reference to exemplary embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but that the invention will include all embodiments falling within the scope of the appended claims.
The present application claims benefit under 35 U.S.C. § 119 of U.S. Provisional Patent Application No. 62/583,310, filed Nov. 8, 2017, entitled “ELECTRONIC BREATH ACTUATED IN-LINE DROPLET DELIVERY DEVICE WITH SINGLE USE AMPOULE AND METHODS OF USE”, the contents of which are each herein incorporated by reference in its entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2018/059874 | 11/8/2018 | WO |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2019/094628 | 5/16/2019 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3934585 | Maurice | Jan 1976 | A |
| 3970250 | Drews | Jul 1976 | A |
| 5021701 | Takahashi et al. | Jun 1991 | A |
| 5164740 | Ivri | Nov 1992 | A |
| 5239993 | Evans | Aug 1993 | A |
| 5363842 | Mishelevich et al. | Nov 1994 | A |
| 5487378 | Robertson | Jan 1996 | A |
| 5497763 | Lloyd et al. | Mar 1996 | A |
| 5586550 | Ivri et al. | Dec 1996 | A |
| 5607410 | Branch | Mar 1997 | A |
| 5630793 | Rowe | May 1997 | A |
| 5724959 | McAughey et al. | Mar 1998 | A |
| 5758637 | Ivri et al. | Jun 1998 | A |
| 5826570 | Goodman et al. | Oct 1998 | A |
| 5828394 | Khuri-Yakub et al. | Oct 1998 | A |
| 5881716 | Wirch et al. | Mar 1999 | A |
| 5884620 | Gonda et al. | Mar 1999 | A |
| 5894841 | Voges | Apr 1999 | A |
| 5906202 | Schuster et al. | May 1999 | A |
| 5938117 | Ivri | Aug 1999 | A |
| 5979247 | Kizawa | Nov 1999 | A |
| 6011062 | Schneider et al. | Jan 2000 | A |
| 6026809 | Abrams et al. | Feb 2000 | A |
| 6062212 | Davison et al. | May 2000 | A |
| 6071498 | Narodylo et al. | Jun 2000 | A |
| 6085740 | Ivri et al. | Jul 2000 | A |
| 6158431 | Poole | Dec 2000 | A |
| 6196219 | Hess et al. | Mar 2001 | B1 |
| 6235177 | Borland et al. | May 2001 | B1 |
| 6358058 | Strupat et al. | Mar 2002 | B1 |
| 6443146 | Voges | Sep 2002 | B1 |
| 6511718 | Paz de Araujo et al. | Jan 2003 | B1 |
| 6523762 | Luginbuhl et al. | Feb 2003 | B1 |
| 6615826 | Gabrio et al. | Sep 2003 | B1 |
| 6629524 | Goodall et al. | Oct 2003 | B1 |
| 6637430 | Voges et al. | Oct 2003 | B1 |
| 6896910 | Kim et al. | May 2005 | B2 |
| 6978941 | Litherland et al. | Dec 2005 | B2 |
| 6981499 | Anderson et al. | Jan 2006 | B2 |
| 7131599 | Katase | Nov 2006 | B2 |
| 7191777 | Brand et al. | Mar 2007 | B2 |
| 7198044 | Trueba | Apr 2007 | B2 |
| 7219664 | Ruckdeschel et al. | May 2007 | B2 |
| 7628339 | Ivri et al. | Dec 2009 | B2 |
| 7648957 | Heyden et al. | Jan 2010 | B2 |
| 7708011 | Hochrainer et al. | May 2010 | B2 |
| 7883031 | Collins, Jr. et al. | Feb 2011 | B2 |
| 7900625 | Kleinstreuer et al. | Mar 2011 | B2 |
| 7954486 | Papania et al. | Jun 2011 | B2 |
| 7976140 | Umeda | Jul 2011 | B2 |
| 8012136 | Collins, Jr. et al. | Sep 2011 | B2 |
| 8367734 | Gao et al. | Feb 2013 | B1 |
| 8474452 | Gumaste et al. | Jul 2013 | B2 |
| 8545463 | Collins, Jr. et al. | Oct 2013 | B2 |
| 8555874 | Fink et al. | Oct 2013 | B2 |
| 8616195 | Power et al. | Dec 2013 | B2 |
| 8684980 | Hunter et al. | Apr 2014 | B2 |
| 8733935 | Ballou, Jr. et al. | May 2014 | B2 |
| 8753308 | Palmer et al. | Jun 2014 | B2 |
| 8936021 | Collins, Jr. | Jan 2015 | B2 |
| 8985100 | Minocchieri et al. | Mar 2015 | B2 |
| 9022027 | Addington et al. | May 2015 | B2 |
| 9087145 | Ballou, Jr. et al. | Jul 2015 | B2 |
| 9227029 | Addington et al. | Jan 2016 | B2 |
| 9242054 | Fink et al. | Jan 2016 | B2 |
| 9352108 | Reed et al. | May 2016 | B1 |
| 9452274 | Addington et al. | Sep 2016 | B2 |
| 9463486 | Wilkerson et al. | Oct 2016 | B2 |
| 9539604 | Wilkerson et al. | Jan 2017 | B2 |
| 9956360 | Germinario et al. | May 2018 | B2 |
| 9962507 | Germinario et al. | May 2018 | B2 |
| 10449314 | Germinario et al. | Oct 2019 | B2 |
| 10525220 | Hunter et al. | Jan 2020 | B2 |
| 10568543 | Yan | Feb 2020 | B2 |
| 10857310 | Muellinger et al. | Dec 2020 | B2 |
| 10898666 | Germinario et al. | Jan 2021 | B2 |
| 20020002975 | Power | Jan 2002 | A1 |
| 20020032387 | Geva et al. | Mar 2002 | A1 |
| 20020046750 | Gonda et al. | Apr 2002 | A1 |
| 20020071871 | Snyder et al. | Jun 2002 | A1 |
| 20020077369 | Noolandi et al. | Jun 2002 | A1 |
| 20020121274 | Borland et al. | Sep 2002 | A1 |
| 20030062042 | Wensley et al. | Apr 2003 | A1 |
| 20030072717 | Reinhold et al. | Apr 2003 | A1 |
| 20030098022 | Nakao et al. | May 2003 | A1 |
| 20030101991 | Trueba | Jun 2003 | A1 |
| 20030127538 | Patel et al. | Jul 2003 | A1 |
| 20030140921 | Smith et al. | Jul 2003 | A1 |
| 20030150445 | Power et al. | Aug 2003 | A1 |
| 20030196654 | Stein | Oct 2003 | A1 |
| 20030205229 | Crockford et al. | Nov 2003 | A1 |
| 20040009231 | Jackson et al. | Jan 2004 | A1 |
| 20040045547 | Yamamoto et al. | Mar 2004 | A1 |
| 20040084044 | Childers et al. | May 2004 | A1 |
| 20040139963 | Ivri et al. | Jul 2004 | A1 |
| 20040195403 | Atterbury et al. | Oct 2004 | A1 |
| 20040215157 | Peclat et al. | Oct 2004 | A1 |
| 20040256487 | Collins, Jr. et al. | Dec 2004 | A1 |
| 20050011514 | Power et al. | Jan 2005 | A1 |
| 20050077315 | Pavlu et al. | Apr 2005 | A1 |
| 20050121025 | Gamard et al. | Jun 2005 | A1 |
| 20050150489 | Dunfield et al. | Jul 2005 | A1 |
| 20050172476 | Stone et al. | Aug 2005 | A1 |
| 20050172958 | Singer et al. | Aug 2005 | A1 |
| 20050217666 | Fink et al. | Oct 2005 | A1 |
| 20050224075 | Childers et al. | Oct 2005 | A1 |
| 20050236501 | Zimlich, Jr. et al. | Oct 2005 | A1 |
| 20070023036 | Grychowski et al. | Feb 2007 | A1 |
| 20070044793 | Kleinstreuer et al. | Mar 2007 | A1 |
| 20070083677 | Cecka et al. | Apr 2007 | A1 |
| 20070119968 | Collins, Jr. et al. | May 2007 | A1 |
| 20070119969 | Collins, Jr. et al. | May 2007 | A1 |
| 20070125370 | Denyer et al. | Jun 2007 | A1 |
| 20070157931 | Parker et al. | Jul 2007 | A1 |
| 20070240714 | Dunne et al. | Oct 2007 | A1 |
| 20070248645 | Bague et al. | Oct 2007 | A1 |
| 20070267010 | Fink et al. | Nov 2007 | A1 |
| 20080000470 | Minocchieri et al. | Jan 2008 | A1 |
| 20080059228 | Bossi et al. | Mar 2008 | A1 |
| 20080142010 | Weaver et al. | Jun 2008 | A1 |
| 20080243050 | Power et al. | Oct 2008 | A1 |
| 20080271732 | Weaver et al. | Nov 2008 | A1 |
| 20080283049 | Mahoney et al. | Nov 2008 | A1 |
| 20080283057 | Rohrschneider et al. | Nov 2008 | A1 |
| 20080295827 | Kobayashi | Dec 2008 | A1 |
| 20080308096 | Borgschulte et al. | Dec 2008 | A1 |
| 20090038610 | Bogh et al. | Feb 2009 | A1 |
| 20090093772 | Genosar | Apr 2009 | A1 |
| 20090101144 | Gamard et al. | Apr 2009 | A1 |
| 20090107492 | Ooida | Apr 2009 | A1 |
| 20090114218 | Veatch | May 2009 | A1 |
| 20090114742 | Collins, Jr. | May 2009 | A1 |
| 20090118243 | Gjorstrup | May 2009 | A1 |
| 20090134235 | Ivri | May 2009 | A1 |
| 20090167812 | Asai et al. | Jul 2009 | A1 |
| 20090192443 | Collins, Jr. | Jul 2009 | A1 |
| 20090212133 | Collins, Jr. | Aug 2009 | A1 |
| 20090235925 | Power et al. | Sep 2009 | A1 |
| 20090270752 | Coifman | Oct 2009 | A1 |
| 20090272818 | Valpey, III et al. | Nov 2009 | A1 |
| 20090314292 | Overfield et al. | Dec 2009 | A1 |
| 20090317496 | Park et al. | Dec 2009 | A1 |
| 20100037894 | Rouse et al. | Feb 2010 | A1 |
| 20100078013 | Power et al. | Apr 2010 | A1 |
| 20100089395 | Power et al. | Apr 2010 | A1 |
| 20100156995 | Kanda et al. | Jun 2010 | A1 |
| 20100181387 | Zaffaroni et al. | Jul 2010 | A1 |
| 20100222752 | Collins, Jr. et al. | Sep 2010 | A1 |
| 20100273895 | Stinchcomb et al. | Oct 2010 | A1 |
| 20100282247 | Kadrichu et al. | Nov 2010 | A1 |
| 20110094523 | Thorens et al. | Apr 2011 | A1 |
| 20110108025 | Fink et al. | May 2011 | A1 |
| 20110114090 | Piper | May 2011 | A1 |
| 20110230820 | Lillis et al. | Sep 2011 | A1 |
| 20110253139 | Guthrie et al. | Oct 2011 | A1 |
| 20110253140 | Smyth et al. | Oct 2011 | A1 |
| 20110253805 | Lee | Oct 2011 | A1 |
| 20120037154 | Gallem et al. | Feb 2012 | A1 |
| 20120048265 | Smaldone | Mar 2012 | A1 |
| 20120092416 | Platt et al. | Apr 2012 | A1 |
| 20120266878 | Watanabe et al. | Oct 2012 | A1 |
| 20120291781 | Kaufmann et al. | Nov 2012 | A1 |
| 20130064777 | Tamarkin et al. | Mar 2013 | A1 |
| 20130079732 | Burt et al. | Mar 2013 | A1 |
| 20130150812 | Hunter et al. | Jun 2013 | A1 |
| 20130172830 | Hunter et al. | Jul 2013 | A1 |
| 20130239956 | Schulz et al. | Sep 2013 | A1 |
| 20130267864 | Addington et al. | Oct 2013 | A1 |
| 20130269684 | Patton | Oct 2013 | A1 |
| 20130284165 | Krimsky | Oct 2013 | A1 |
| 20130299607 | Wilkerson et al. | Nov 2013 | A1 |
| 20130319404 | Feriani et al. | Dec 2013 | A1 |
| 20130327323 | Rubin | Dec 2013 | A1 |
| 20130330400 | Perkins et al. | Dec 2013 | A1 |
| 20130334335 | Wilkerson et al. | Dec 2013 | A1 |
| 20130334339 | Xu | Dec 2013 | A1 |
| 20140037735 | Montgomery | Feb 2014 | A1 |
| 20140116426 | Mullinger et al. | May 2014 | A1 |
| 20140187969 | Hunter et al. | Jul 2014 | A1 |
| 20140190496 | Wensley et al. | Jul 2014 | A1 |
| 20140213925 | Chan et al. | Jul 2014 | A1 |
| 20140230817 | Richardson | Aug 2014 | A1 |
| 20140231538 | Tabata et al. | Aug 2014 | A1 |
| 20140283859 | Minskoff et al. | Sep 2014 | A1 |
| 20140336618 | Wilkerson et al. | Nov 2014 | A1 |
| 20150018694 | Gomo | Jan 2015 | A1 |
| 20150101596 | Hogan | Apr 2015 | A1 |
| 20150136129 | Mahadevan et al. | May 2015 | A1 |
| 20150136155 | Verleur et al. | May 2015 | A1 |
| 20150164375 | Schindhelm et al. | Jun 2015 | A1 |
| 20150174348 | Tunnell et al. | Jun 2015 | A1 |
| 20150196060 | Wensley et al. | Jul 2015 | A1 |
| 20150273165 | Hadash | Oct 2015 | A1 |
| 20150283339 | Mahadevan et al. | Oct 2015 | A1 |
| 20150328151 | Ballou, Jr. et al. | Nov 2015 | A1 |
| 20150352301 | Stedman et al. | Dec 2015 | A1 |
| 20160001018 | Fink et al. | Jan 2016 | A1 |
| 20160001019 | Fink et al. | Jan 2016 | A1 |
| 20160082208 | Ballam et al. | Mar 2016 | A1 |
| 20160106341 | Adam et al. | Apr 2016 | A1 |
| 20160129182 | Schuster et al. | May 2016 | A1 |
| 20160166768 | Edwards et al. | Jun 2016 | A1 |
| 20160213864 | Eilat et al. | Jul 2016 | A1 |
| 20160213866 | Tan | Jul 2016 | A1 |
| 20160245830 | Mace et al. | Aug 2016 | A1 |
| 20160310982 | Von Hollen | Oct 2016 | A1 |
| 20160325055 | Cameron | Nov 2016 | A1 |
| 20160354557 | McPherson Allnutt et al. | Dec 2016 | A1 |
| 20170007449 | Nielsen | Jan 2017 | A1 |
| 20170035924 | Yang et al. | Feb 2017 | A1 |
| 20170039344 | Bitran et al. | Feb 2017 | A1 |
| 20170106153 | Davidson et al. | Apr 2017 | A1 |
| 20170106155 | Reed et al. | Apr 2017 | A1 |
| 20170128677 | Eilat et al. | May 2017 | A1 |
| 20170158776 | Feltquate et al. | Jun 2017 | A1 |
| 20170203058 | Davidson et al. | Jul 2017 | A1 |
| 20170203323 | Gschwind et al. | Jul 2017 | A1 |
| 20170224706 | Surber | Aug 2017 | A1 |
| 20170270260 | Shetty et al. | Sep 2017 | A1 |
| 20170274163 | Oliveras et al. | Sep 2017 | A1 |
| 20170304565 | Allosery | Oct 2017 | A1 |
| 20170304566 | Allosery | Oct 2017 | A1 |
| 20170319796 | Germinario et al. | Nov 2017 | A1 |
| 20170319797 | Germinario et al. | Nov 2017 | A1 |
| 20170333646 | Hemy et al. | Nov 2017 | A1 |
| 20180021528 | Hsieh et al. | Jan 2018 | A1 |
| 20180021530 | Fink | Jan 2018 | A1 |
| 20180056018 | Canvin et al. | Mar 2018 | A1 |
| 20180116871 | Hunter et al. | May 2018 | A1 |
| 20180193175 | Bluecher et al. | Jul 2018 | A1 |
| 20180317557 | Monsees et al. | Nov 2018 | A1 |
| 20180344955 | Germinario et al. | Dec 2018 | A1 |
| 20180369515 | Germinario et al. | Dec 2018 | A1 |
| 20190117907 | Germinario et al. | Apr 2019 | A1 |
| 20190125985 | Germinario et al. | May 2019 | A1 |
| 20190125986 | Germinario et al. | May 2019 | A1 |
| 20190125987 | Germinario et al. | May 2019 | A1 |
| 20190134330 | Germinario et al. | May 2019 | A1 |
| 20190224426 | Farina et al. | Jul 2019 | A1 |
| 20190343793 | Gunther et al. | Nov 2019 | A1 |
| 20190358420 | Hunter et al. | Nov 2019 | A1 |
| 20200060346 | Danek | Feb 2020 | A1 |
| 20200147325 | Wilson et al. | May 2020 | A1 |
| 20200230329 | Danek | Jul 2020 | A1 |
| 20200246556 | Osoegawa et al. | Aug 2020 | A1 |
| 20200276398 | Hebrank et al. | Sep 2020 | A1 |
| 20200289770 | Hebrank et al. | Sep 2020 | A1 |
| 20200315842 | Palanker et al. | Oct 2020 | A1 |
| 20200345588 | Merrell et al. | Nov 2020 | A1 |
| 20210106772 | Hebrank et al. | Apr 2021 | A1 |
| 20210236745 | Germinario et al. | Aug 2021 | A1 |
| 20210275760 | Hunter et al. | Sep 2021 | A1 |
| 20220001122 | Hunter et al. | Jan 2022 | A1 |
| 20220296823 | Hebrank et al. | Sep 2022 | A1 |
| Number | Date | Country |
|---|---|---|
| 2012258488 | Jan 2013 | AU |
| 2364248 | Aug 2006 | CA |
| 715947 | Nov 2020 | CH |
| 1788806 | Jun 2006 | CN |
| 104511072 | Apr 2015 | CN |
| 204995458 | Jan 2016 | CN |
| 205019058 | Feb 2016 | CN |
| 0923957 | Oct 2001 | EP |
| 2724741 | Apr 2014 | EP |
| 3127616 | Feb 2017 | EP |
| H11-042219 | Feb 1999 | JP |
| 2003-265994 | Sep 2003 | JP |
| 2006-68508 | Mar 2006 | JP |
| 10-2019-122453 | Oct 2019 | KR |
| WO 9312823 | Jul 1993 | WO |
| WO 9609846 | Apr 1996 | WO |
| WO 9614163 | May 1996 | WO |
| WO 9848873 | Nov 1998 | WO |
| WO 0010634 | Mar 2000 | WO |
| WO 0047335 | Aug 2000 | WO |
| WO 0050112 | Aug 2000 | WO |
| WO 0185244 | Nov 2001 | WO |
| WO 0187378 | Nov 2001 | WO |
| WO 02068128 | Sep 2002 | WO |
| WO 03020349 | Mar 2003 | WO |
| WO 03059413 | Jul 2003 | WO |
| WO 2004078025 | Sep 2004 | WO |
| WO 2006013952 | Feb 2006 | WO |
| WO 2006083014 | Aug 2006 | WO |
| WO 2006102345 | Sep 2006 | WO |
| WO 2006108558 | Oct 2006 | WO |
| WO 2007107160 | Sep 2007 | WO |
| WO 2008056986 | May 2008 | WO |
| WO 2008058941 | May 2008 | WO |
| WO 2008116165 | Sep 2008 | WO |
| WO 2009012371 | Jan 2009 | WO |
| WO 2009111612 | Sep 2009 | WO |
| WO 2010065452 | Jun 2010 | WO |
| WO 2011042212 | Apr 2011 | WO |
| WO 2011083377 | Jul 2011 | WO |
| WO 2011091268 | Jul 2011 | WO |
| WO 2011163272 | Dec 2011 | WO |
| WO 2012026963 | Mar 2012 | WO |
| WO 2013098334 | Jul 2013 | WO |
| WO 2013158352 | Oct 2013 | WO |
| WO 2013158967 | Oct 2013 | WO |
| WO 2013173321 | Nov 2013 | WO |
| WO 2014147550 | Sep 2014 | WO |
| WO 2015004554 | Jan 2015 | WO |
| WO 2015106150 | Jul 2015 | WO |
| WO 2015136529 | Sep 2015 | WO |
| WO 2015176033 | Nov 2015 | WO |
| WO 2015191478 | Dec 2015 | WO |
| WO 2015191481 | Dec 2015 | WO |
| WO 2016001923 | Jan 2016 | WO |
| WO 2016001924 | Jan 2016 | WO |
| WO 2016003738 | Jan 2016 | WO |
| WO 2017015303 | Jan 2017 | WO |
| WO 2017056103 | Apr 2017 | WO |
| WO 2018213834 | Nov 2018 | WO |
| WO 2019071008 | Apr 2019 | WO |
| WO 2019079461 | Apr 2019 | WO |
| WO 2019136437 | Jul 2019 | WO |
| WO 2019219865 | Nov 2019 | WO |
| WO 2019219873 | Nov 2019 | WO |
| WO 2020072478 | Apr 2020 | WO |
| WO 2020141424 | Jul 2020 | WO |
| WO 2020154497 | Jul 2020 | WO |
| WO 2020227717 | Nov 2020 | WO |
| WO 2020264501 | Dec 2020 | WO |
| WO 2021090135 | May 2021 | WO |
| WO 2021203038 | Oct 2021 | WO |
| WO 2022051496 | Mar 2022 | WO |
| WO 2022226407 | Oct 2022 | WO |
| WO 2023064477 | Apr 2023 | WO |
| WO 2023091637 | May 2023 | WO |
| Entry |
|---|
| Copley, “Understanding cascade impaction and its importance for inhaler testing,” Copley Scientific, Copley White Paper [serial online], Jul. 2007 [retrieved on May 7, 2017]. Retrieved from the Internet: URL: http://www.copleyscientific.com/files/ww/articles/Understanding%20Cascade%20Impaction%20White%20Paper.pdf; 6 pp. |
| Kharitonov, “Exhaled markers of inflammatory lung diseases: ready for routine monitoring?” Swiss Med Wkly, 2004; 134: 175-192. |
| Broeders et al., “Inhalation Profiles in Asthmatics and COPD Patients: Reproducibility and Effect of Instruction,” Journal of Aerosol Medicine, vol. 16, No. 2, 2003, 131-141. |
| Taube et al., “Use of a portable device to record maximum inspiratory flow in relation to dyspnea in patients with COPD,” Respiratory Medicine, 2011, 105, 316-312. |
| Steller, “Microcontroller Based Diagnostic Smart Inhaler,” University of Cincinnati, Dec. 7, 2014, 63 pages. |
| Carvalho et al., “The function and performance of aqueous aerosol devices for inhalation therapy,” Journal of Pharmacy and Pharmacology, vol. 68, No. 5, Apr. 8, 2016, pp. 556-578. |
| Pneuma Respiratory, Digitally breath-actuated inhaler device with precision droplet ejector technology and digital dose confidence. Available on Mar. 18, 2017 [retrieved on Jun. 30, 2017]. Retrieved from the Internet: URL: https://pneumarespiratory.com/. 3 pp. |
| Azzopardi, “Sauter Mean Diameter” Sep. 30, 2012, 4 pages, https://web.archive.org/web/20120930225842/http://www.termopedia.com/content/1108, retrieved May 26, 2014. |
| Number | Date | Country | |
|---|---|---|---|
| 20200353186 A1 | Nov 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62583310 | Nov 2017 | US |
